Spyre Therapeutics, Inc. (SYRE)
91.40
+6.68
(+7.88%)
USD |
NASDAQ |
Oct 20, 16:00
91.75
+0.35
(+0.38%)
After-Hours: 20:00
Spyre Therapeutics Gross Profit (TTM) : 0.00 for June 30, 2026
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.272M |
| December 31, 2023 | -0.078M |
| September 30, 2023 | -0.40M |
| June 30, 2023 | -0.728M |
| March 31, 2023 | -0.85M |
| December 31, 2022 | 0.365M |
| September 30, 2022 | 3.829M |
| June 30, 2022 | 4.157M |
| March 31, 2022 | 4.007M |
| December 31, 2021 | 2.679M |
| September 30, 2021 | -0.995M |
| June 30, 2021 | -1.405M |
| March 31, 2021 | -1.781M |
| December 31, 2020 | -1.624M |
| September 30, 2020 | -1.344M |
| Date | Value |
|---|---|
| June 30, 2020 | -1.039M |
| March 31, 2020 | -0.77M |
| December 31, 2019 | -0.564M |
| September 30, 2019 | -0.384M |
| June 30, 2019 | -0.355M |
| March 31, 2019 | -0.248M |
| December 31, 2018 | -0.148M |
| September 30, 2018 | -0.076M |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | -0.017M |
| September 30, 2015 | -0.029M |
| June 30, 2015 | -0.029M |
| March 31, 2015 | -0.029M |
| December 31, 2014 | -0.012M |
Gross Profit Definition
Annual, Interim and Preliminary Items - Commercial, Other Financial Companies
Gross Profit (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit (TTM) Benchmarks
| AbbVie, Inc. | 45.98B |
| Incyte Corp. | 5.320B |
| SELLAS Life Sciences Group, Inc. | 0.00 |
| Relay Therapeutics, Inc. | 8.139M |
| ACADIA Pharmaceuticals, Inc. | 1.038B |